Form 4: Pharvaris Executive Sells Shares Under 10b5-1 Plan

Pharvaris N.V. Chief Medical Officer Lu Peng executed a Rule 10b5-1 trading plan, involving the exercise of stock options and sale of common stock.

Summary

• Lu Peng, Chief Medical Officer of Pharvaris N.V., reported transactions on May 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.
• The plan involved the exercise of stock options and the subsequent sale of common stock.
• A total of 14,166 shares were acquired through option exercise at a price of $2.59 per share.
• Following these transactions, 14,023 shares were sold at a weighted average price of $30.1637, with individual sales ranging from $30.00 to $30.99.
• An additional 143 shares were also sold at $31.
• The reporting person retains beneficial ownership of 66,226 shares of common stock after these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by an executive can be a negative signal, the execution under a Rule 10b5-1 plan and the significant profit realized suggest a planned financial event rather than a lack of confidence.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially non-insider trading related activity.
• The weighted average sale price of $30.1637 is significantly higher than the exercise price of $2.59, indicating a profitable transaction for the executive.
• The executive still holds a substantial number of shares (66,226) after the sale, suggesting continued confidence in the company.

Negatives

• A significant number of shares (14,166) were sold by a key executive, which could be perceived negatively by the market.
• The sale of shares, even under a 10b5-1 plan, reduces the executive's direct stake in the company.

Risks

• The filing does not explicitly mention any risks associated with these transactions, as it is a standard disclosure of stock activity.
• Potential market perception of insider selling, despite the 10b5-1 plan, could be a risk.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a report of past transactions.

Management Comments

• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan.
• The shares were sold in connection with the exercise of stock options in a cashless exercise transaction.
• The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that Form 4 filings reporting stock option exercises and sales under Rule 10b5-1 plans are common for executives in the biotechnology and pharmaceutical sectors, especially when stock prices have appreciated significantly since the options were granted. This allows executives to diversify their holdings and realize gains in a structured manner.

Stakeholder Impact

• Shareholders: May interpret the sale as a sign of reduced insider confidence, although the 10b5-1 plan mitigates this concern. The sale also increases the float of publicly available shares.
• Employees: May view the executive's profitable sale as a positive indicator of the company's stock performance, but also potentially as a signal of reduced insider commitment.
• Management: The executive is realizing personal financial gains, which is a standard outcome of stock option plans.

Next Steps

• No specific next steps are mentioned in the filing related to future transactions or company strategy.
• The reporting person may continue to execute transactions under the 10b5-1 plan if it remains active.

Key Dates

Keywords

Pharvaris N.V., PHVS, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Stock Sale, Beneficial Ownership, Lu Peng, Chief Medical Officer